Medico Remedies has announced securing a substantial order worth ₹73.00 crore, marking a significant business development for the pharmaceutical company. The order represents a notable addition to the company's order book and demonstrates market confidence in its product offerings.

Order Details and Business Impact

The secured order, valued at ₹73.00 crore, constitutes a material business development for Medico Remedies. This substantial order value reflects the company's ability to secure significant contracts in the pharmaceutical sector.

Market Position

With a current market capitalisation of ₹390.00 crore, Medico Remedies operates as a mid-cap pharmaceutical company. The secured order represents approximately 18.72% of the company's total market value, underscoring its material significance to the overall business operations.

Business Significance

The order win demonstrates several key aspects of Medico Remedies' business position:

• Strong market demand for the company's pharmaceutical products
• Ability to secure substantial contracts in competitive markets
• Enhanced order book providing revenue visibility
• Validation of the company's product quality and market positioning

This development strengthens Medico Remedies' business prospects and provides a solid foundation for future operations in the pharmaceutical sector.

Medico Remedies Limited has secured a significant legal victory as the Bombay High Court quashed show cause notices issued by the GST Authority, effectively nullifying a GST demand of Rs 2.94 crore for the financial years 2017-18, 2018-19, and 2019-20.

Legal Proceedings and Outcome

The company had filed Writ Petition no.10974 of 2025 challenging the show cause notice issued by the Directorate General of Goods & Services Tax Intelligence, Office of the Pr. Additional Director General, Mumbai. The High Court's decision to quash the notices comes as a relief to Medico Remedies, as it eliminates the potential financial burden that the GST demand would have imposed.

Financial Implications

According to the company's disclosure, the court's decision results in no financial impact on Medico Remedies. The potential liability of Rs 2.94 crore, which could have affected the company's finances for three fiscal years, has been averted due to this favorable legal outcome.

Company's Response and Commitment

In its regulatory filing, Medico Remedies acknowledged a delay in disclosing the initial show cause notice, stating that it was inadvertently missed. The company has committed to ensuring timely disclosures in the future, emphasizing its dedication to maintaining transparency with investors and regulatory bodies.

Regulatory Compliance

The company made this disclosure in compliance with Regulation 30 of SEBI Listing Regulations, read with Master Circular No.SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. This adherence to regulatory requirements demonstrates Medico Remedies' commitment to keeping shareholders and the market informed about significant legal and financial developments.

This legal victory not only removes a substantial financial uncertainty for Medico Remedies but also reinforces the importance of due process in tax-related matters for businesses operating in India's pharmaceutical sector.